- Vaccine Name: KINRIX
- Target Pathogen: Poliovirus
- Target Disease: Polio
- Product Name: Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus Vaccine
- Tradename: KINRIX
- Manufacturer: GlaxoSmithKline
- Vaccine Ontology ID: VO_0000067
- CDC CVX code: 130
- Type: Toxoid vaccine + Subunit vaccine + Inactivated or "killed" vaccine
- Status: Licensed
- Location Licensed: USA
- Host Species for Licensed Use: Human
- Antigen: Each 0.5-mL dose is formulated to contain 25 Lf of diphtheria toxoid, 10 Lf of tetanus toxoid, 25 mcg of inactivated pertussin toxin (PT), 25 mcg of filamentous hemagglutinin (FHA), 8 mcg of pertactin (69 kiloDalton outer membrane protein), 40 D-antigen Units (DU) of Type 1 poliovirus (Mahoney), 8 DU of Type 2 poliovirus (MEF-1), and 32 DU of Type 3 poliovirus (Saukett).
- Allergen: Latex, Neomycin, Polymyxin B.
- Immunization Route: Intramuscular injection (i.m.)
- Storage: Store refrigerated between 2° and 8°C (36° and 46°F), do not freeze.
- Approved Age for Licensed Use: 4 to 6 years of age.
- Description: KINRIX (Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus Vaccine) is a noninfectious, sterile vaccine for intramuscular administration. Each 0.5-mL dose is formulated to contain 25 Lf of diphtheria toxoid, 10 Lf of tetanus toxoid, 25 mcg of inactivated pertussis toxin (PT), 25 mcg of filamentous hemagglutinin (FHA), 8 mcg of pertactin (69 kiloDalton outer membrane protein), 40 D-antigen Units (DU) of Type 1 poliovirus
183 (Mahoney), 8 DU of Type 2 poliovirus (MEF-1), and 32 DU of Type 3 poliovirus (Saukett). The diphtheria, tetanus, and pertussis components of KINRIX are the same as those in INFANRIX and PEDIARIX and the poliovirus component is the same as that in PEDIARIX. (FDA: KINRIX)
|
